ASX Growth Companies With High Insider Ownership To Watch In June 2024

In This Article:

As the ASX200 shows signs of a positive shift, buoyed by favorable movements in international markets and anticipation around the RBA's interest rate decision, investors are keenly watching for opportunities. In this environment, growth companies with high insider ownership on the ASX stand out as potentially strong candidates due to their aligned interests between management and shareholders.

Top 10 Growth Companies With High Insider Ownership In Australia

Name

Insider Ownership

Earnings Growth

Hartshead Resources (ASX:HHR)

13.9%

86.3%

Cettire (ASX:CTT)

28.7%

30.1%

Gratifii (ASX:GTI)

17%

112.4%

Acrux (ASX:ACR)

14.6%

115.3%

Doctor Care Anywhere Group (ASX:DOC)

28.4%

96.4%

Plenti Group (ASX:PLT)

12.8%

106.4%

Hillgrove Resources (ASX:HGO)

10.4%

45.4%

Change Financial (ASX:CCA)

26.6%

85.4%

Botanix Pharmaceuticals (ASX:BOT)

11.4%

120.9%

Liontown Resources (ASX:LTR)

16.4%

63.9%

Click here to see the full list of 91 stocks from our Fast Growing ASX Companies With High Insider Ownership screener.

Let's take a closer look at a couple of our picks from the screened companies.

Botanix Pharmaceuticals

Simply Wall St Growth Rating: ★★★★★★

Overview: Botanix Pharmaceuticals Limited, based in Australia, focuses on the research and development of dermatology and antimicrobial products, with a market capitalization of approximately A$519.80 million.

Operations: The company generates revenue primarily from its research and development activities in the dermatology and antimicrobial sectors, totaling A$0.44 million.

Insider Ownership: 11.4%

Revenue Growth Forecast: 120.4% p.a.

Botanix Pharmaceuticals, with less than A$1m in revenue, is poised for significant growth. The company's earnings are expected to surge by 120.89% annually, outpacing the Australian market's average. Despite a recent dilution of shareholders, Botanix maintains high insider ownership and is forecasted to achieve a robust return on equity of 43.9% in three years. However, its financial runway is under one year, highlighting potential short-term funding challenges as it approaches the commercial launch of SofdraÔ.

ASX:BOT Earnings and Revenue Growth as at Jun 2024
ASX:BOT Earnings and Revenue Growth as at Jun 2024

Mesoblast

Simply Wall St Growth Rating: ★★★★★☆

Overview: Mesoblast Limited is a biotechnology company focused on developing regenerative medicine products, operating in Australia, the United States, Singapore, and Switzerland, with a market capitalization of approximately A$1.24 billion.